ECSP21034253A - Métodos sintéticos mejorados para elaborar compuestos heterocíclicos fusionados como moduladores del receptor de orexina - Google Patents
Métodos sintéticos mejorados para elaborar compuestos heterocíclicos fusionados como moduladores del receptor de orexinaInfo
- Publication number
- ECSP21034253A ECSP21034253A ECSENADI202134253A ECDI202134253A ECSP21034253A EC SP21034253 A ECSP21034253 A EC SP21034253A EC SENADI202134253 A ECSENADI202134253 A EC SENADI202134253A EC DI202134253 A ECDI202134253 A EC DI202134253A EC SP21034253 A ECSP21034253 A EC SP21034253A
- Authority
- EC
- Ecuador
- Prior art keywords
- orexin receptor
- synthetic methods
- heterocyclic compounds
- receptor modulators
- fused heterocyclic
- Prior art date
Links
- 108050000742 Orexin Receptor Proteins 0.000 title abstract 2
- 102000008834 Orexin receptor Human genes 0.000 title abstract 2
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 238000010189 synthetic method Methods 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 102000002512 Orexin Human genes 0.000 abstract 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 abstract 1
- SQOCEMCKYDVLMM-UHFFFAOYSA-N [2-(4,6-dimethylpyrimidin-2-yl)-1,3,3a,4,6,6a-hexahydropyrrolo[3,4-c]pyrrol-5-yl]-[2-fluoro-6-(triazol-2-yl)phenyl]methanone Chemical compound CC1=CC(C)=NC(N2CC3CN(CC3C2)C(=O)C=2C(=CC=CC=2F)N2N=CC=N2)=N1 SQOCEMCKYDVLMM-UHFFFAOYSA-N 0.000 abstract 1
- 238000010961 commercial manufacture process Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 206010022437 insomnia Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 108060005714 orexin Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940075993 receptor modulator Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Health & Medical Sciences (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Se describen procesos para preparar (((3aR,6aS)-5-(4,6-dimetilpirimidin-2-il)hexahidropirrolo[3,4-c]pirrol-2(1H)-il)(2-fluoro-6-(2H-1,2,3-triazol-2-il)fenil)metanona, que son útiles para la fabricación comercial. Dicho compuesto es un modulador del receptor de orexina y puede ser útil en composiciones farmacéuticas y métodos para el tratamiento de estados de enfermedad, trastornos y afecciones mediadas por la actividad de la orexina, tales como insomnio y depresión.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862760995P | 2018-11-14 | 2018-11-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP21034253A true ECSP21034253A (es) | 2021-06-30 |
Family
ID=70730771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202134253A ECSP21034253A (es) | 2018-11-14 | 2021-05-14 | Métodos sintéticos mejorados para elaborar compuestos heterocíclicos fusionados como moduladores del receptor de orexina |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US12030887B2 (es) |
| EP (2) | EP3880204B1 (es) |
| JP (1) | JP7398452B2 (es) |
| KR (1) | KR102777062B1 (es) |
| CN (1) | CN113038952B (es) |
| AR (1) | AR117074A1 (es) |
| AU (1) | AU2019380072B2 (es) |
| BR (1) | BR112021009211A2 (es) |
| CR (1) | CR20210240A (es) |
| EA (1) | EA202191356A1 (es) |
| EC (1) | ECSP21034253A (es) |
| ES (2) | ES3060483T3 (es) |
| HR (1) | HRP20240743T1 (es) |
| HU (1) | HUE066708T2 (es) |
| IL (1) | IL283067A (es) |
| JO (1) | JOP20210110A1 (es) |
| MA (2) | MA54250A (es) |
| MX (1) | MX2021005698A (es) |
| PE (1) | PE20211470A1 (es) |
| PH (1) | PH12021551054A1 (es) |
| PL (1) | PL3880204T3 (es) |
| RS (1) | RS65638B1 (es) |
| SG (1) | SG11202104886YA (es) |
| SM (1) | SMT202400265T1 (es) |
| TW (1) | TW202039452A (es) |
| WO (1) | WO2020100011A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022194122A1 (zh) * | 2021-03-16 | 2022-09-22 | 上海翰森生物医药科技有限公司 | 含氮杂环的多环化合物及其制备方法和应用 |
| AU2023340064A1 (en) * | 2022-09-14 | 2025-03-20 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Free base crystal form of polycyclic compound of nitrogen-containing heterocycle, and preparation method therefor |
| TW202440545A (zh) * | 2022-12-12 | 2024-10-16 | 大陸商江蘇恩華藥業股份有限公司 | 取代四氫環戊基〔ｃ〕吡咯衍生物、製備方法、中間體及其用途 |
| WO2024189472A1 (en) | 2023-03-14 | 2024-09-19 | Janssen Pharmaceutica Nv | Improved synthetic methods of making substituted pyrimidine intermediates for synthesis of orexin receptor modulators |
| AU2024305901A1 (en) | 2023-06-29 | 2026-02-12 | Janssen Pharmaceutica Nv | Method of treating depression using seltorexant |
| WO2025242852A1 (en) | 2024-05-24 | 2025-11-27 | Janssen Pharmaceutica Nv | Seltorexant for use in treating major depressive disorder with insomnia symptoms |
| CN118598880B (zh) * | 2024-08-07 | 2024-11-26 | 艾斯拓康生物医药(天津)有限公司 | 一类含氮桥环化合物及其制备方法和应用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4341403A1 (de) | 1993-12-04 | 1995-06-08 | Basf Ag | N-substituierte 3-Azabicycloalkan-Derivate, ihre Herstellung und Verwendung |
| US6809105B2 (en) | 2000-04-27 | 2004-10-26 | Abbott Laboratories | Diazabicyclic central nervous system active agents |
| MY145722A (en) | 2000-04-27 | 2012-03-30 | Abbott Lab | Diazabicyclic central nervous system active agents |
| US20050065178A1 (en) | 2003-09-19 | 2005-03-24 | Anwer Basha | Substituted diazabicycloakane derivatives |
| US7399765B2 (en) | 2003-09-19 | 2008-07-15 | Abbott Laboratories | Substituted diazabicycloalkane derivatives |
| ES2434467T3 (es) | 2005-05-13 | 2013-12-16 | Lexicon Pharmaceuticals, Inc. | Compuestos multicíclicos y métodos para su uso |
| US20060258691A1 (en) | 2005-05-13 | 2006-11-16 | Joseph Barbosa | Methods and compositions for improving cognition |
| GB0510204D0 (en) | 2005-05-19 | 2005-06-22 | Chroma Therapeutics Ltd | Enzyme inhibitors |
| CA2668811A1 (en) | 2006-11-07 | 2008-06-05 | Lexicon Pharmaceuticals, Inc. | Methods of treating cognitive impairment and dementia |
| CA2709514A1 (en) | 2007-12-21 | 2009-07-02 | Astrazeneca Ab | Bicyclic derivatives for use in the treatment of androgen receptor associated conditions |
| WO2011050202A1 (en) * | 2009-10-23 | 2011-04-28 | Janssen Pharmaceutica Nv | Fused heterocyclic compounds as orexin receptor modulators |
| ME03452B (me) | 2009-10-23 | 2020-01-20 | Janssen Pharmaceutica Nv | Disupstituisani oktahi-dropirolo[3,4-c]piroli kao modulatori oreksin receptora |
| WO2012145581A1 (en) * | 2011-04-20 | 2012-10-26 | Janssen Pharmaceutica Nv | Disubstituted octahy-dropyrrolo [3,4-c] pyrroles as orexin receptor modulators |
| WO2015150252A1 (en) | 2014-04-01 | 2015-10-08 | Bayer Cropscience Ag | Use of heterocyclic compounds for controlling nematodes |
| WO2016100157A2 (en) * | 2014-12-19 | 2016-06-23 | Merck Sharp & Dohme Corp. | 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists |
| EP3287454B1 (en) * | 2015-04-24 | 2020-09-02 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| MD3426251T2 (ro) | 2016-03-10 | 2022-09-30 | Janssen Pharmaceutica Nv | Metode de tratament al depresiei utilizând antagoniști ai receptorului orexină-2 |
| GB201702174D0 (en) | 2017-02-09 | 2017-03-29 | Benevolentai Bio Ltd | Orexin receptor antagonists |
-
2019
- 2019-11-11 WO PCT/IB2019/059677 patent/WO2020100011A1/en not_active Ceased
- 2019-11-11 ES ES24175622T patent/ES3060483T3/es active Active
- 2019-11-11 CN CN201980075378.9A patent/CN113038952B/zh active Active
- 2019-11-11 US US17/293,291 patent/US12030887B2/en active Active
- 2019-11-11 BR BR112021009211-0A patent/BR112021009211A2/pt unknown
- 2019-11-11 SM SM20240265T patent/SMT202400265T1/it unknown
- 2019-11-11 MA MA054250A patent/MA54250A/fr unknown
- 2019-11-11 ES ES19885791T patent/ES2988132T3/es active Active
- 2019-11-11 PE PE2021000698A patent/PE20211470A1/es unknown
- 2019-11-11 JP JP2021526230A patent/JP7398452B2/ja active Active
- 2019-11-11 EP EP19885791.4A patent/EP3880204B1/en active Active
- 2019-11-11 HU HUE19885791A patent/HUE066708T2/hu unknown
- 2019-11-11 MA MA71707A patent/MA71707A/fr unknown
- 2019-11-11 MX MX2021005698A patent/MX2021005698A/es unknown
- 2019-11-11 AU AU2019380072A patent/AU2019380072B2/en not_active Expired - Fee Related
- 2019-11-11 EA EA202191356A patent/EA202191356A1/ru unknown
- 2019-11-11 SG SG11202104886YA patent/SG11202104886YA/en unknown
- 2019-11-11 RS RS20240662A patent/RS65638B1/sr unknown
- 2019-11-11 CR CR20210240A patent/CR20210240A/es unknown
- 2019-11-11 HR HRP20240743TT patent/HRP20240743T1/hr unknown
- 2019-11-11 KR KR1020217016208A patent/KR102777062B1/ko active Active
- 2019-11-11 EP EP24175622.0A patent/EP4428136B1/en active Active
- 2019-11-11 PL PL19885791.4T patent/PL3880204T3/pl unknown
- 2019-11-12 TW TW108140931A patent/TW202039452A/zh unknown
- 2019-11-14 AR ARP190103344A patent/AR117074A1/es not_active Application Discontinuation
-
2021
- 2021-05-05 PH PH12021551054A patent/PH12021551054A1/en unknown
- 2021-05-10 IL IL283067A patent/IL283067A/en unknown
- 2021-05-14 EC ECSENADI202134253A patent/ECSP21034253A/es unknown
- 2021-05-16 JO JOP/2021/0110A patent/JOP20210110A1/ar unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP21034253A (es) | Métodos sintéticos mejorados para elaborar compuestos heterocíclicos fusionados como moduladores del receptor de orexina | |
| ECSP19047936A (es) | Imidazopirrolopiridina como inhibidores de la familia de quinasas jak | |
| CO6541572A2 (es) | Octahidropirrolo[3.4-c]pirrolos distituidos como moduladores del receptor de orexina | |
| SV2018005800A (es) | Moduladores alostéricos positivos del receptor muscarínico de acetilcolina m4 | |
| BR112016000195A8 (pt) | compostos heterocíclicos, composição farmacêutica, combinação, seu uso, e método para inibir uma atividade da tirosina quinase btk ou jak, egfr, alk, pdgfr, blk, bmx/etk, flt3(d835y), itk, tec, txk, e suas respectivas vias | |
| UY32968A (es) | Compuestos heterocíclicos fusionados como moduladores del receptor de orexina | |
| ECSP19042688A (es) | Inhibidores de moléculas pequeñas de la familia de quinasas jak | |
| PE20211001A1 (es) | Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b | |
| UY32967A (es) | Compuestos heterocíclicos fusionados como moduladores del receptor de la orexina | |
| SA521421575B1 (ar) | مُعدلات ليباز أُحادِيُّ الجلِيسِريد | |
| MX387394B (es) | Compuestos heterociclicos como inhibidores de la cinasa ret. | |
| CO2021016860A2 (es) | Pirazolo piridinas heteroaromáticas sustituidas y su uso como moduladores del receptor glun2b | |
| CL2009000400A1 (es) | Compuestos heterociclicos derivados de 3-fenil-1,6- naftiridin-2-ona; moduladores de la actividad cinasa; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como trastornos alergicos, trastornos autoinmunes, neoplasias, rechazo en trasplante de organos, entre otras. | |
| CL2021001547A1 (es) | Derivados de 7-fenoxi-n-(3-azabiciclo[3.2.1]octan-8-il)-6,7-dihidro-5h-pirrolo[1,2-b][1,2,4]triazol-2-amina y compuestos relacionados como moduladores de gamma-secretasa para el tratamiento de la enfermedad de alzheimer | |
| PE20212196A1 (es) | Compuestos, composiciones, y metodos para modular la actividad cdk9 | |
| MX2021015969A (es) | Compuestos heterocíclicos para mediar la actividad de la tirosina cinasa 2. | |
| MX390505B (es) | Compuestos de [1,2,4]triazolo[1,5-a]pirimidina como inhibidores de pde2 | |
| ECSP22016630A (es) | Métodos sintéticos mejorados para la elaboración de compuestos de (2h-1,2,3-triazol-2-il)fenilo como moduladores del receptor de orexina | |
| MX2022011310A (es) | Azabiciclo y derivados de diazepina para tratar trastornos oculares. | |
| UY36010A (es) | NUEVOS COMPUESTOS DERIVADOS DE 6,7-DIHIDRO-3H-OXAZOLO[3,4-a]PIRAZINA-5,8-DIONA | |
| CR20190283A (es) | Imidazopyrrolopyridine as inhibitors of the jak family of kinases |